文献速递胸部肿瘤

奥希替尼一线治疗晚期表皮生长因子受体突变阳性非小细胞肺癌的真实世界研究(OSI-FACT)

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
PubMed 文献 · Eur J Cancer · 2021-11-05

OSI-FACT是一项回顾性多中心队列研究,纳入538例2018年8月至2019年12月间接受奥希替尼初始治疗的EGFR突变阳性患者,中位观察期14.7个月,中位无进展生存期20.5个月(95%CI 18.6-未达到)。多因素分析显示男性、恶性积液、肝转移、晚期不可切除、突变类型及PD-L1表达与PFS相关;219例停药患者中因疾病进展停药占44.3%、肺炎占25.5%、其他不良事件占16.0%。

要点

  • 538例EGFR突变阳性患者奥希替尼初始治疗的中位PFS为20.5个月(95%CI 18.6-未达到)。
  • 男性、恶性积液、肝转移、晚期不可切除、L858R及罕见突变、PD-L1表达与PFS相关。
  • 219例停药患者中疾病进展占44.3%、肺炎占25.5%、其他不良事件占16.0%。

核心结论

  • 奥希替尼初始治疗期间,PD-L1表达与PFS显著相关,不良事件是值得注意的停药原因。

研究设计与样本

  • 回顾性多中心队列研究,纳入538例2018年8月至2019年12月间接受奥希替尼初始治疗的EGFR突变阳性患者。
  • 主要结局为无进展生存期(PFS)。

主要发现

  • 中位观察期为14.7个月(四分位距11.4-20.0)。
  • 中位PFS为20.5个月(95%CI 18.6-未达到)。
  • 多因素分析显示男性(HR 1.99,95%CI 1.35-2.93,P=0.001)、恶性积液(HR 1.51,95%CI 1.11-2.04,P=0.008)、肝转移(HR 1.55,95%CI 1.03-2.33,P=0.037)、晚期不可切除(HR 1.71,95%CI 1.04-2.82,P=0.036)与PFS相关。
  • L858R突变(HR 1.55,95%CI 1.01-2.38,P=0.043)和罕见突变(HR 3.15,95%CI 1.70-5.83,P<0.001)与PFS相关。
  • PD-L1表达1-49%(HR 1.66,95%CI 1.05-2.63,P=0.029)、≥50%(HR 2.24,95%CI 1.17-4.30,P=0.015)及未知(HR 1.53,95%CI 1.05-2.22,P=0.026)与PFS相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osimertinib is the standard of care in the initial treatment for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer. However, clinical data and reliable prognostic biomarkers are insufficient. METHODS: We performed a retrospective multicentre cohort study for 538 EGFR mutation-positive patients, who received osimertinib as the initial treatment between August 2018 and December 2019. The main outcome was progression-free survival (PFS). RESULTS: The median observation period was 14.7 months (interquartile range 11.4-20.0). The median PFS was 20.5 months (95% confidence interval [CI] 18.6-not reached). Multivariate analysis showed that sex (male) (hazard ratio [HR] 1.99, 95% CI 1.35-2.93, P = 0.001), malignant effusions (HR 1.51, 95% CI 1.11-2.04, P = 0.008), liver metastasis (HR 1.55, 95% CI 1.03-2.33, P = 0.037), advanced unresectable cases (HR 1.71, 95% CI, 1.04-2.82, P = 0.036), mutation type and programmed cell death-ligand 1 (PD-L1) expression were associated with PFS. The L858R (HR 1.55, 95% CI 1.01-2.38, P = 0.043) and uncommon mutations (HR 3.15, 95% CI 1.70-5.83, P < 0.001) were associated with PFS. PD-L1 expression of 1-49% (HR 1.66, 95% CI 1.05-2.63, P = 0.029), ≥50% (HR 2.24, 95% CI 1.17-4.30, P = 0.015) and unknown (HR 1.53, 95% CI 1.05-2.22, P = 0.026) was associated with PFS. The main reasons for treatment discontinuation among 219 patients were disease progression (44.3%), pneumonitis (25.5%) and other adverse events (16.0%). CONCLUSION: During initial treatment with osimertinib, PD-L1 expression is significantly related to PFS. Adverse events are a noteworthy reason for discontinuation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sakata Y, Sakata S, Oya Y, et al. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer. 2021. PMID: 34749119. doi:10.1016/j.ejca.2021.09.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。